MHRA Agrees with Galmed’s Plan to use Aramchol meglumine in the Randomized Double-blind Placebo-Controlled Part of the Phase 3 ARMOR studyGalmed Pharmaceuticals Ltd. • August 16th, 2021 • Pharmaceutical preparations
- MHRA agreement follows similar agreement from the FDA which allows Galmed to proceed with its proposed clinical studies with Aramchol meglumine in lieu of Aramchol free acid without the need to repeat nonclinical and clinical studies
